SWITCH: a randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC)

Fischer von Weikersthal, L. and Goebell, P. J. and de Santis, M. and Lerchenmueller, C. and Zimmermann, U. and Bos, M. M. E. M. and Freier, W. and Schirrmacher-Memmel, S. and Staehler, M. and Pahernik, S. and Los, M. and Schenck, M. and Floercken, A. and van Arkel, C. and Hauswald, K. and Indorf, M. and Gottstein, D. and Eichelberg, C. and Michel, M. S. (2014) SWITCH: a randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC). ONCOLOGY RESEARCH AND TREATMENT, 37 (Suppl5). p. 5. ISSN 2296-5270, 2296-5262

Full text not available from this repository.
Item Type: Article
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Urologie
Depositing User: Petra Gürster
Date Deposited: 07 Aug 2020 05:55
Last Modified: 07 Aug 2020 05:55
URI: https://pred.uni-regensburg.de/id/eprint/9409

Actions (login required)

View Item View Item
pred is powered by EPrints 3.4 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.